Consistently, different studies on lung, skin, bladder, ovary, colon, and other tumor types show that blocking of SETDB1 and other H3K9me3-related proteins sensitizes tumors to ICB treatment [33,34,79,81,87,88,89]. Here, SETDB1 is linked to neoplasm.